An open-label, uncontrolled, multi-center phase II study to investigate efficacy, safety and pharmacokinetic of ONO-4538 in relapsed/refractory Hodgkin Lymphoma patients

Trial Profile

An open-label, uncontrolled, multi-center phase II study to investigate efficacy, safety and pharmacokinetic of ONO-4538 in relapsed/refractory Hodgkin Lymphoma patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 13 Jun 2016 New trial record
    • 07 Jun 2016 Interim nalysis presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top